Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Susan G Panzer-Knodle"'
Autor:
Norman A. Abood, Anita K. Salyers, Beatrice B. Taite, Susan G. Panzer-Knodle, Osman D. Suleymanov, Nancy S. Nicholson, Leo G. Frederick, Robert J. Anders, James A. Szalony, Jimmy D. Page
Publikováno v:
ChemInform. 32
A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes, and restenosis after percutaneous interventions. Antiplatelet agents that have a wider spectrum of activity than aspirin,
Autor:
Michael S. South, John J. Parlow, James A Szalony, Rhonda M. Lachance, Susan G Panzer-Knodle, Jason D. Blom, Rhonda S Wood, Anita K. Salyers, Brenda L. Case, Nancy S. Nicholson, Osman D. Suleymanov
Publikováno v:
Thrombosis research. 112(3)
Introduction : Pharmacological treatment of deep vein thrombosis (DVT) in the future may target inhibitors of specific procoagulant proteins. This study used a non-human primate model to test the effect of PHA-798, a specific inhibitor of the tissue
Autor:
Robert J. Anders, Susan G. Panzer-Knodle, Jimmy D. Page, Nancy S. Nicholson, Beatrice B. Taite, Norman A. Abood, Anita K. Salyers, Osman D. Suleymanov, Leo G. Frederick, James A. Szalony
Publikováno v:
Medicinal research reviews. 21(3)
A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes, and restenosis after percutaneous interventions. Antiplatelet agents that have a wider spectrum of activity than aspirin,
Autor:
Nancy S. Nicholson, J. G. Rico, Kenneth Williams, Foe S. Tjoeng, P. R. Bovy, Lucy W. King, Anita K. Salyers, Lori Ann Schretzman, Beatrice B. Taite, Robert B. Garland, Masateru Miyano, Susan G. Panzer-Knodle, Jeffery A. Zablocki, R. J. Lindmark, Mihaly V. Toth, Dudley E. McMackins, James G. Campion, Mark E. Zupec, Larry P. Feigen, Steven Paul Adams
Publikováno v:
Bioorganicmedicinal chemistry. 3(5)
A novel series of orally active fibrinogen receptor antagonists has been discovered through structural modification of our lead intravenous (iv) antiplatelet agent, 5-(4-amidinophenyl)pentanoyl-Asp-Phe 1 (SC-52012). The Asp-Phe amide bond was removed